Management of Low IgA Levels

Diagnostic Classification and Risk Stratification

The American Academy of Allergy, Asthma, and Immunology recommends assessing specific antibody production to pneumococcal polysaccharides and protein antigens, as this functional assessment is more predictive of infection risk than IgA levels alone 2, 1
Selective IgA deficiency (SIGAD) is defined as IgA absent with normal IgG and IgM levels, normal B cells, and normal vaccine responses, according to the Journal of Allergy and Clinical Immunology 2, 3
Partial IgA deficiency may progress to complete SIGAD or evolve into common variable immunodeficiency (CVID) in 20-25% of cases with family history 1, 4

The American College of Allergy, Asthma, and Immunology suggests that recurrent sinopulmonary infections occur in approximately 18-19% of IgA-deficient patients, particularly when associated with impaired pneumococcal antibody responses 1
Atopic disease is present in 18-19% of IgA-deficient patients, with allergic inflammation predisposing to secondary respiratory infections 1
Viral respiratory infections, particularly rhinovirus, occur more frequently in IgA-deficient patients 3

The Infectious Diseases Society of America recommends treating acute infections with aggressive antimicrobial therapy using longer courses than in immunocompetent patients 1
Target encapsulated bacteria and atypical organisms, and consider prophylactic antibiotics for patients with recurrent infections that negatively impact quality of life 3, 1
IgG replacement therapy should be considered only for patients with severe phenotype, treatment failure, or documented impaired specific antibody production, according to the Immune Deficiency Foundation 1, 5

Patients with very low or absent IgA may develop anti-IgA antibodies, creating risk for anaphylactic reactions to blood products, and should use IgA-deficient blood products when available for transfusions 1
Reassess immune function regularly, as some patients progress from partial IgA deficiency to SIGAD or CVID over time, and repeat immunoglobulin levels and specific antibody testing if clinical status changes 1, 4